Apollo Investment (NASDAQ:AINV) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 18.6 percent decrease over earnings of $0.43 per share from the same period last year.
Canaccord Genuity Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $16
Canaccord Genuity analyst Whitney Ijem initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $16.
